

# CLINICAL TRIAL

NCT03913143 - ILLUMINATE

Pediatric Ophthalmology



**A double-masked, randomized, controlled, multiple-dose study to evaluate the efficacy, safety, tolerability and systemic exposure of QR-110 in Subjects with Leber's Congenital Amaurosis (LCA) due to c.2991+1655A>G mutation (p.Cys998X) in the CEP290 gene (Illuminate)**

Rare Eye Disease concerned by the trial :  
Leber Congenital Amaurosis

Status of the trial : Recruiting  
Orphan drug recognition : No

Inclusion criteria : [click here to see detailed criteria](#)

Exclusion criteria : [click here to see detailed criteria](#)



Inclusion opening date: 04/04/2019



Inclusion closing date (previsional): 12/2020

Children



Adults



## Within ERN-EYE members



Locations of the trial :

**Ghent University**, Ghent, Belgium

**CHNO des XV XX - Centre Hospitalier National d'Ophthalmologie**, Paris, France


**Strasbourg University Hospital - CARGO**  
Strasbourg, France

**Center for Ophthalmic Research, University of Tübingen**  
Tübingen, Germany

**Justus-Liebig University Giessen**  
Giessen, Germany

**Radboud University Medical Center**,  
Nijmegen, Netherlands

**Moorfields Eye Hospital - Moorfields Eye Hospital**  
London, United Kingdom, EC1V 2PD



Funder type : Industry

[More informations](#)